IL130785A0 - Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same - Google Patents

Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same

Info

Publication number
IL130785A0
IL130785A0 IL13078598A IL13078598A IL130785A0 IL 130785 A0 IL130785 A0 IL 130785A0 IL 13078598 A IL13078598 A IL 13078598A IL 13078598 A IL13078598 A IL 13078598A IL 130785 A0 IL130785 A0 IL 130785A0
Authority
IL
Israel
Prior art keywords
medicament
patient
treating
manufacture
pharmaceutical compositions
Prior art date
Application number
IL13078598A
Other languages
English (en)
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of IL130785A0 publication Critical patent/IL130785A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13078598A 1997-01-10 1998-01-09 Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same IL130785A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3467297P 1997-01-10 1997-01-10
US4015497P 1997-03-07 1997-03-07
PCT/US1998/000573 WO1998030241A1 (fr) 1997-01-10 1998-01-09 Procedes d'administration therapeutique de composes anti-cd40l

Publications (1)

Publication Number Publication Date
IL130785A0 true IL130785A0 (en) 2001-01-28

Family

ID=26711241

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13078598A IL130785A0 (en) 1997-01-10 1998-01-09 Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same

Country Status (21)

Country Link
US (2) US20020071840A1 (fr)
EP (1) EP0966302B1 (fr)
JP (1) JP2001508450A (fr)
KR (2) KR100632846B1 (fr)
CN (1) CN1248921A (fr)
AT (1) ATE356634T1 (fr)
AU (1) AU721697B2 (fr)
BR (1) BR9807471A (fr)
CA (1) CA2277223A1 (fr)
CZ (1) CZ244399A3 (fr)
DE (1) DE69837322T2 (fr)
EA (1) EA001426B1 (fr)
EE (1) EE9900275A (fr)
HK (1) HK1024424A1 (fr)
IL (1) IL130785A0 (fr)
IS (1) IS5101A (fr)
NO (1) NO993275L (fr)
NZ (1) NZ337073A (fr)
PL (1) PL193966B1 (fr)
TR (1) TR199902192T2 (fr)
WO (1) WO1998030241A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
BR9809641A (pt) * 1997-05-17 2000-07-11 Biogen Inc Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto
TR199903141T2 (xx) * 1997-06-20 2000-09-21 Biogen, Inc. Terap�tik protein engelleyici sendrom i�in CD154 blokaj tedavisi.
CZ20011021A3 (cs) * 1998-09-21 2001-10-17 Genetics Institute, Inc. Způsoby tlumení imunitní odpovědi na terapeutické proteiny
EP1101495A4 (fr) * 1999-06-01 2003-05-07 Eisai Co Ltd Agents prophylactiques du purpura thrombocytopenique idiopathique
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
WO2001066141A1 (fr) * 2000-03-06 2001-09-13 Eisai Co., Ltd. Agents therapeutiques et prophylactiques diriges contre le syndrome des antiphospholipides
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
CA2876779A1 (fr) 2000-05-12 2001-11-22 Genzyme Corporation Modulateurs de marquage du tnf-.alpha.
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
US7217718B2 (en) * 2002-11-21 2007-05-15 Genzyme Corporation Induction of immune tolerance
ES2650267T3 (es) 2008-12-05 2018-01-17 Als Therapy Development Institute Método para el tratamiento de enfermedades neurodegenerativas

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
ATE179616T1 (de) * 1993-09-02 1999-05-15 Dartmouth College Verfahren zur verlaengerter unterdrueckung der humoralen immunitaet
CN1127351C (zh) * 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性ｔ细胞耐受的方法
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
JPH09507074A (ja) * 1993-12-23 1997-07-15 イミュネックス・コーポレーション Ｃｄ４０を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
PT892643E (pt) * 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito

Also Published As

Publication number Publication date
PL193966B1 (pl) 2007-04-30
AU5735398A (en) 1998-08-03
KR100632846B1 (ko) 2006-10-16
EP0966302A1 (fr) 1999-12-29
DE69837322T2 (de) 2007-11-22
EA001426B1 (ru) 2001-02-26
US20050158314A1 (en) 2005-07-21
US20020071840A1 (en) 2002-06-13
HK1024424A1 (en) 2000-10-13
BR9807471A (pt) 2000-03-21
KR20000070035A (ko) 2000-11-25
EE9900275A (et) 2000-02-15
TR199902192T2 (xx) 1999-12-21
NZ337073A (en) 2001-01-26
EA199900633A1 (ru) 2000-02-28
WO1998030241A1 (fr) 1998-07-16
EP0966302B1 (fr) 2007-03-14
CN1248921A (zh) 2000-03-29
DE69837322D1 (de) 2007-04-26
NO993275L (no) 1999-09-09
IS5101A (is) 1999-06-30
PL334500A1 (en) 2000-02-28
KR20050088494A (ko) 2005-09-06
JP2001508450A (ja) 2001-06-26
ATE356634T1 (de) 2007-04-15
AU721697B2 (en) 2000-07-13
CA2277223A1 (fr) 1998-07-16
NO993275D0 (no) 1999-07-01
CZ244399A3 (cs) 1999-10-13

Similar Documents

Publication Publication Date Title
IL130785A0 (en) Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same
TW265265B (fr)
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
MD1367C2 (ro) Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
HK1040363A1 (en) Use of daptomycin
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
PL398445A1 (pl) Kompozycje farmaceutyczne zawierające dekstrometorfan i chininę do leczenia zaburzeń neurologicznych
IL130784A0 (en) Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with immune complex disease and pharmaceutical compositions containing the same
HUP0001263A2 (hu) Eljárások anti-CD4OL vegyületek gyógyászati alkalmazásaira
YU61598A (sh) Tretmani bolesti uz korišćenje citokina
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
MXPA02004654A (es) Metodos para el tratamiento y prevencion de trastornos neurodegenerativos.
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
FR2791894B1 (fr) Utilisation d'interferon beta dans le traitement de la tumeur d'ewing